Showing 1 - 10 of 694,909
Who gains from more information on the quality of pharmaceutical drugs? Are there incentives for voluntary post-approval clinical trials among pharmaceutical companies? Contrary to popular belief, this paper shows that it is not in the consumer interest that clinical evidence establishing the...
Persistent link: https://www.econbiz.de/10010281440
Regulators of new products confront a tradeoff between speeding a new product to market and collecting additional product quality information. The FDA's Breakthrough Therapy Designation (BTD) provides an opportunity to understand if a regulator can use new policy to innovate around this...
Persistent link: https://www.econbiz.de/10013477204
This paper studies the interaction between two dynamic domains, (1) an evolutionary biological system ('the environment') whose behaviour determines the availability of a resource stock, and (2) an industry where access to the resource stock is determined by the outcome of a patent race. The...
Persistent link: https://www.econbiz.de/10011597824
This paper studies the effect of two regulatory instruments - a price cap and a reference price system - a mandatory substitution rule, and the combination of both on generic competition in a Salop-type model with an off-patent brand-name drug and n differentiated generic versions. The price cap...
Persistent link: https://www.econbiz.de/10010510801
In this paper, I study the effect of parallel trade (cross border resale of goods without the authorization of the manufacturer) on pharmaceutical regulation in a North-South framework with a firms endogenous decision to export to the South. Governments in both countries may limit prices...
Persistent link: https://www.econbiz.de/10012889817
In this paper, I study the effect of parallel trade (cross border resale of goods without the authorization of the manufacturer) on pharmaceutical regulation in a North-South framework with a firm's endogenous decision to export to the South. Governments in both countries may limit prices...
Persistent link: https://www.econbiz.de/10011986314
In 1996, following an epidemic, Pfizer tested a new drug on 200 children in Muslim Nigeria. 11 children died while others were disabled. We study the effects of the disclosure, in 2000, of the deaths of Muslim children in the Pfizer trials on vaccine compliance among Muslim mothers. Muslim...
Persistent link: https://www.econbiz.de/10014372412
The year of 1997 witnessed an important change in direct-to-consumer (DTC) advertising of prescription drugs. For the first time, the Food and Drug Administration (FDA) permitted brand-specific DTC ads on TV without a "brief summary" of comprehensive risk information. This led to a three-fold...
Persistent link: https://www.econbiz.de/10014031773
The world’s leading pharmaceutical laboratories are racing to complete trials and begin marketing an effective SARS-CoV-2 vaccine. International Health Organizations and National Public Health Agencies are charged with setting standards for successful completion of Phase 3 trials. Brand...
Persistent link: https://www.econbiz.de/10014093633
Using econometric evidence, this article confirms that distribution of medicines online is split into two market segments of very diverse quality, and identifies the factors that drive quality and quality assurance in this activity. Unlike fraudulent, 'rogue,' websites, which offer scant...
Persistent link: https://www.econbiz.de/10014116683